$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne

{"summary": "Commenter believes there is still time to buy MAIA before its interim data readout.", "reason": "Author expresses own directional judgment (get in) on MAIA with concrete catalyst (interim data readout).", "ideas": [{"symbol": "MAIA", "direction": "long", "thesis": "The author suggests investors can still get into MAIA before the interim data readout, implying the catalyst is the upcoming interim data for this Phase 3 oncology company. The mechanism is that positive interim data would re-rate the stock, and entering before it captures that move. No specific risk or timeframe is stated beyond the interim data event.", "thesis_short": "Buy MAIA before interim data readout", "quote": "I think we still can get in before the interim data", "confidence": 0.55, "sentiment": 0.6, "timeframe": "before interim data"}], "model": "deepseek-v4-flash", "verified": true, "extraction_model": "deepseek-v4-flash"}